Picard Medical, Inc. (NYSE American: PMI) announced that NYSE American LLC has accepted its plan to regain compliance with the exchange's continued listing standards under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.

The acceptance allows Picard Medical to continue listing and trading its common stock on NYSE American under the ticker symbol "PMI" while executing the operational, strategic, and financial initiatives outlined in its plan. The company has been granted a compliance period through November 8, 2027, subject to periodic review by NYSE American and continued compliance with all other applicable listing standards.

"We are pleased that the NYSE American has accepted our compliance plan, providing a clear path forward as we continue executing our long-term strategy," said Richard Fang, Interim Chief Executive Officer of Picard Medical.

Picard Medical is the parent company of SynCardia Systems LLC, which makes the SynCardia Total Artificial Heart, a device it claims is the only commercially available total artificial heart in the United States and Canada. The company states the device has been implanted in more than 2,100 patients across 27 countries.